Lignocain B. Braun Melsungen (Lidocaine Hydrochloride Monohydrate)

Lidocaine blocks voltage‑gated sodium channels on nerve membranes, preventing sodium influx that is essential for action potential generation. This interruption stops nerve impulse propagation, producing a reversible loss of sensation in the area where the drug is administered.

The specific dose of Lignocain is determined by the prescribing clinician based on the intended procedure, patient weight, age, and clinical condition. Healthcare professionals calculate the appropriate concentration and volume to achieve effective anesthesia while minimizing systemic exposure.

Safety data for lidocaine in pregnancy and lactation are limited. It is classified as a Category B drug in many regions, indicating no proven risk in animal studies but insufficient human data. Use during pregnancy or while breastfeeding should only occur when the potential benefit outweighs any possible risk, as decided by the treating physician.

To order Lignocain, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lignocain (lidocaine) offers a rapid onset of action (1–3 minutes) and moderate duration (30–120 minutes) compared with agents like bupivacaine, which has a slower onset but longer duration. Lidocaine’s favorable safety profile and versatility for multiple routes (epidural, intradermal, intravenous) make it a common first‑line choice for short‑ to medium‑duration procedures.

Lignocain should be stored at room temperature, preferably below 25 °C, in its original sealed container. Protect the solution from direct sunlight, excessive heat, and moisture. Do not freeze. Inspect the vial for particulate matter or discoloration before use, and discard any product that appears compromised.

Lignocain is administered by a qualified healthcare professional via injection. The route—epidural, intradermal, or intravenous—depends on the clinical indication. Proper aseptic technique, correct needle placement, and dosage calculation are essential to achieve effective anesthesia and reduce the risk of systemic toxicity.

Serious risks include cardiovascular toxicity such as arrhythmias, heart block, or cardiac arrest, and central nervous system toxicity leading to seizures or respiratory depression. Rare but severe allergic reactions (anaphylaxis) and methemoglobinemia can also occur, especially in patients with pre‑existing enzyme deficiencies.

Lignocain is contraindicated in patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics, as well as in individuals with severe hepatic impairment that could impair drug metabolism. Caution is also advised for patients with significant cardiac conduction disorders or those taking interacting medications listed under major interactions.